ARC Medical Devices currently has a Fucoidan based product, PERIDAN® Concentrate, on the veterinary market for the reduction of surgical adhesions in horses, foals, and rabbits. PERIDAN® Concentrate has many advantages over the marketed competition in the field of preventing surgical adhesions, and ARC Medical Devices is currently working to develop a similar product with the goal of entering the human market. PERIDAN® Concentrate and ARC’s test article are easier to administer, more effective at reducing the number of surgical adhesions, and more effective at reducing the severity of surgical adhesions than any device currently marketed for the prevention of surgical adhesions. The initial studies have indicated that ARC’s product could revolutionize the field of adhesion prevention and become standard practice once approved, reducing the number and severity of adhesions by 65% and 76% respectively.
For more information on PERIDAN® Concentrate, click here.
One of PERIDAN® Concentrate’s two main advantages is its ease of application. PERIDAN® Concentrate and ARC’s test article are administered directly to the surgery site at the end of a surgical procedure prior to the final closing of the site. It is very difficult to predict exactly where adhesions will form, and these product’s liquid form allows them to flow throughout and coat the entire surgical site with the PERIDAN polymer while other products must be directly applied to the specific site where they hope to prevent adhesions. By covering the entire surgical site, ARC’s products do not require the same precision and are more effective at preventing adhesions throughout the entire surgical area. Furthermore, the direct application required by the currently marketed products may inadvertently cause additional adhesions.
To learn more about surgical adhesions, click here.
ARC’s test article and PERIDAN® Concentrate’s mechanism of action is thought to be due to these product’s physical form. These propriety liquid medical devices consist of a sulphated, high molecular weight polysaccharide called Fucoidan dissolved in a physiological salt solution. These solutions are easily administered at the end of a surgical procedure immediately prior to the final closing of the surgical site. When applied, the solution will flow throughout the surgical site and coat the tissues with the PERIDAN polymer, separating any damaged areas for the first stages of tissue repair. The solution is then broken down into simple sugars and metabolized by the body, leaving the surgical site free of adhesions and the coating.
ARC Medical Devices Inc. controls issued patents and active patent applications for three different, unique patent families that provide protection of ARC’s PERIDAN® products. Patent Family #1 is owned by The University of British Columbia (UBC), is exclusively licensed by ARC Medical Devices Inc., contains issued patents in 35 territories, and will expire in 2022. Patent Family #2 and Patent Family #3 belong to ARC, will expire in 2025 and 2030 respectively, and have patent applications pending in numerous territories. Patent Family #3 already has patents issued in 5 territories.